Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1

• Autori principali: Jiong Li (Autore), Xiangjun Ma (Autore), Faying Xu (Autore), Yuanliang Yan (Autore), Weiqing Chen (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

AbstractContext Cholangiocarcinoma with highly heterogeneous, aggressive, and multidrug resistance has a poor prognosis. Although babaodan (BBD) combined with cisplatin improved non-small cell lung cancer efficacy, its impact on overcoming resistance in cholangiocarcinoma remains unexplored.Objectiv...